同时，浙江医疗领域国家人工智能应用中试基地全球创新创业团队招募计划正式启动。基地将提供研发 空间、专项资金与政策支持，面向全球吸引优质AI医疗项目"拎包入驻"，助力医学人工智能从概念验证 到产业落地的全链条发展。 人民财讯9月26日电，第四届全球数字贸易博览会数字医疗健康产业对接会9月25日在杭州举办。会上， 医学人工智能测评验证联合实验室正式揭牌成立。该实验室由浙江省医疗领域国家人工智能应用中试基 地联合中国医学科学院、中国信息通信研究院共同组建，旨在构建医学AI测评验证的"金标准"，推动人 工智能在医疗领域的合规、安全、高效应用。 ...

Core Insights - The integration of VR and AI in healthcare is leading to a quiet revolution, redefining the boundaries of health and wellness, with applications ranging from pain relief to treating Alzheimer's disease [1][12] - Walter Greenleaf, a leading expert in VR and digital health, emphasizes the importance of translating laboratory results into market applications to aid startups in scaling their innovations [2] - Immersive therapies are emerging as a new class of treatment, utilizing VR and AR to help patients overcome psychological barriers in a safe environment [4] Group 1: Immersive Therapy Applications - Immersive therapies are being used for PTSD treatment, addiction recovery, and social training for children with autism, showcasing the potential of VR and AR as "second-generation drugs" [4] - The concept of "on-demand experiences" allows patients to enter virtual worlds that facilitate gradual exposure to their fears and anxieties [4] Group 2: Aging Population and Investment Opportunities - By 2050, one in six people will be over 65, highlighting the need for solutions that maintain brain vitality as longevity increases [6] - The focus on brain health is becoming a more critical investment topic than wealth accumulation, with sleep being identified as a key factor [6] Group 3: China's Opportunities in AI and Healthcare - China possesses significant advantages in AI and healthcare technology, particularly in precision medicine and data application, positioning it for rapid advancements in these fields [8] Group 4: Digital Therapeutics and Regulatory Changes - The FDA has established a new category for "software as a medical device," allowing for the prescription of software, indicating a shift towards mainstream acceptance of digital therapies [10] - The next 5-10 years are expected to see the scaling of immersive medical applications within healthcare systems [10]

AI出现在诊室，像医生一样问病史、做诊断、开检查单。这个曾出现在科幻电影中的场景，正逐渐走 进现实。 今年上半年，"天枢""观心""瑞智病理"等医疗领域大规模预训练语言模型（以下简称"医疗大模型"）在 全国三甲医院密集落地。亿欧智库数据显示，截至2025年5月，国内累计发布医疗大模型达288个，其中 今年新增133个。 这些被临床寄予厚望的技术产物，离成为真正的AI医生还有多远？ 医疗模型价值初显 今年夏天，北京市房山区窦店镇一家基层医院的内科门诊来了一名患儿，半边脸肿大，久不消退。医生 建议家长带孩子去口腔科检查。但检查结果显示，口腔无异常。 焦急的患儿家长再次找到医生。医生想起医院不久前引入的AI儿科医生。这款儿科医疗大模型整合了 300多位知名儿科专家的临床经验及大量脱敏的病历数据，学习了3000多种儿童常见病、疑难病相关诊 疗知识。 医生与这名"博学"的AI儿科医生展开了多轮"对话"。AI提示，患儿可能是腮腺炎。基于AI提醒，诊断最 终被明确，患儿也得到及时治疗。 2024年11月以来，多部门密集出台AI医疗相关政策：《卫生健康行业人工智能应用场景参考指引》梳 理84个细分应用场景；国家医保局将AI辅 ...

作为中国AI医疗变革驱动者，医渡科技秉承"使精准医疗惠及每一个人"的使命，打造专业、高效、精准 且普惠的医学人工智能产品与解决方案。基于公司自主研发的核心算法引擎YiduCore，医渡科技构 建"数据-算法-场景"飞轮闭环，实现了AI技术的高效率创新、低成本规模化应用，推动智能决策赋 能"医-药-险-患者"全产业链生态。 AI医疗的核心是通过提升医学证据质量与生成效率，优化研发、诊断及治疗流程，最终实现更安全、 更优质、更可及的医疗服务。医渡科技持续提升医疗服务效率与可及性，让医生拥有更精准高效的决策 工具，让药企缩短分子到患者距离，让患者享有更可负担的精准诊断和治疗，让公共系统获得更科学的 支撑。医疗AI的价值，体现在对每一个个体生命的尊重与对健康福祉的守护。 医渡科技(02158)公布，近期，公司联属公司天津开心生活科技有限公司中标山东衍渡生物科技有限公 司重组人神经生长因子(SMR001)滴眼液Ⅲ期临床研究项目，项目总金额约为人民币5582万元。 ...

近日，聚焦于AI技术对医学影像市场的变化与未来发展趋势，联影智能高级研发副总裁、首席科学家 高耀宗接受了21世纪经济报道记者的专访。 高耀宗认为，医疗AI目前在临床上主要应用于辅助决策场景。在国内，这类产品大多被划分为高风险 类别，需按照第三类医疗器械进行管理，其审批路径和临床评价要求与传统医疗产品有明显差异。截至 目前，国家药监局已批准上市了100多款AI三类证产品，其中以单模型、单场景的应用占绝大多数。 其表示，"由于医疗领域具备高度严肃性、复杂性和低容错性，在声明医疗AI产品的预期用途时尤为谨 慎，明确将应用场景限定于具体疾病领域，例如肺癌或前列腺癌的辅助检测与诊断，确保产品功能与临 床需求精准对应。" 随着AI技术特别是大模型的迅猛发展，整个行业正面临全新的挑战与变革。"作为人工智能医疗头部企 业，我们不仅在持续推进技术创新，也积极参与到国家药监局审评指导原则、行业标准的制定工作中， 希望能够给监管机构和行业贡献我们的实践和经验，助推行业规范发展。目前，针对临床上复杂场景， 基于大模型的AI产品，无论国内还是国外，均尚未落地。所以，我们在持续推动技术创新的同时，也 紧密关切全球监管政策的动向。" （文 ...

Group 1 - The Federal Reserve is expected to initiate a new round of interest rate cuts, which may lead to a reallocation of international funds, particularly towards emerging markets like China [1] - The Chinese stock market has shown an upward trend, with various indices reaching new highs for the year [1] - Kirsty Desson, head of global small-cap stock investment at Aberdeen Investment, believes that the weak dollar cycle will benefit RMB assets, highlighting potential global investment targets in sectors like biotechnology, consumer applications, and AI in healthcare [1] Group 2 - Since 2025, small-cap stocks have outperformed large-cap stocks, with the Russell 2000 index rising 4.83% in the past month, compared to the S&P 500's 2.1% increase [2] - The MSCI global small-cap index has seen a cumulative increase of 3.67% over the past month and over 11% in three months [2] - Small-cap stocks represent about 15% of the global market capitalization but account for approximately 70% of the total number of listed companies globally [2] Group 3 - The large number of small-cap stocks across various industries provides abundant opportunities for global investors, but selecting quality stocks remains a challenge [3] - The investment philosophy focuses on three key aspects: quality, growth, and momentum [3] - High-quality small-cap stocks can be assessed based on competitive advantages, management capabilities, and financial stability [3] Group 4 - Small-cap stocks are generally more sensitive to interest rate changes, with historical data indicating that they tend to outperform large-cap stocks during the early stages of a rate-cutting cycle [4] Group 5 - There has been a continuous increase in net inflows into emerging market equity funds this year, with a significant rise in funds allocated to Chinese stocks [5] - The A-share market has shown a strong upward trend, with high trading volumes and record inflows from foreign investors [5] Group 6 - The current scale of the Chinese market is relatively small, and many foreign investors are still unfamiliar with it [6] - The shift in global investment patterns from dollar-dominated assets to emerging markets, particularly China, is expected to continue [6] - The "Shanghai-Hong Kong Stock Connect" and "Shenzhen-Hong Kong Stock Connect" have provided effective platforms for foreign investors, enhancing their understanding of the Asian market [6] Group 7 - External factors such as the weakening dollar and geopolitical tensions are prompting investors to reassess their asset allocation strategies [7] - Internal factors like policy adjustments, liquidity improvements, and stronger economic fundamentals are expected to support the Chinese market [7] - The valuation of the A-share market remains attractive, with the CSI 300 index's price-to-earnings ratio around 14 times, still below its five-year average [7] Group 8 - The Chinese capital market is witnessing a revaluation in sectors such as biotechnology, consumer applications, and AI in healthcare [7] - The focus on domestic demand and self-sufficiency is becoming increasingly clear, with innovative Chinese companies, including promising small-cap firms, emerging in the capital market [7] Group 9 - There is an expectation for further favorable policies that will provide more signals regarding growth priorities and consumer orientation, which will bolster market confidence and predictability of corporate earnings [8]

Core Insights - The article highlights the establishment of a national AI application pilot base in the medical field, which aims to enhance the integration of AI in healthcare services and improve patient outcomes [1][6][11] Group 1: AI Application in Healthcare - The AI pilot base serves as a large "incubation factory" where hospitals and enterprises can access services covering the entire process from diagnosis to drug development [1][6] - During the 2025 China International Service Trade Fair, the pilot base showcased 31 AI medical interactive products, including a system for early warning of eye diseases and chronic conditions, which attracted significant public interest [1][3] - The AI eye disease and chronic disease warning system can automatically capture images and generate analysis reports within three minutes, identifying over 30 eye diseases and 10 systemic risks [3][4] Group 2: Infrastructure and Services - The pilot base aims to create a unified support platform for common capabilities, facilitating the standardized and scalable application of AI in healthcare [6][8] - It focuses on two main areas: precision diagnosis and biopharmaceutical manufacturing, providing a comprehensive service system that includes product development and application promotion [7][8] - The base is supported by the Beijing Municipal Development and Reform Commission and the Beijing Municipal Health Commission, with operations managed by a dedicated company [6][7] Group 3: Data Challenges and Solutions - Data challenges, including ownership ambiguity and compliance requirements, are identified as significant obstacles in the development of AI applications in healthcare [9][10] - The pilot base is working on creating a trusted data space to facilitate the safe and efficient use of healthcare data, integrating various medical data resources [9][10] - A medical big model and application evaluation system is being developed to provide authoritative assessments of AI models in real clinical scenarios, ensuring quality and safety in AI applications [10][11] Group 4: Future Vision - The ultimate goal of the pilot base is to leverage AI to enhance healthcare delivery, allowing for early detection of health risks and timely interventions [11] - By connecting medical institutions and enterprises, the base aims to realize the vision of "letting data do the work, reducing patient illness" [11]

Core Viewpoint - The article discusses the integration of AI in healthcare, highlighting the launch of Ant Group's AI health application AQ, which aims to enhance medical services and accessibility for patients, particularly in underserved areas [3][5]. Group 1: AI Health Application Launch - On September 12, Ant Group launched the AI health application AQ at the 2025 Inclusion Bund Conference, introducing a smart body open platform designed to assist doctors and medical institutions in developing personalized AI assistants [3][5]. - The platform aims to address the limited supply of medical services in China, where top-tier hospitals are concentrated in eastern provinces, with only 5% located in western provinces [3][5]. Group 2: Enhancing Doctor's Service Capacity - AQ's platform connects nearly one million doctors and integrates over 200,000 online consultation services, enabling the creation of "AI avatars" for more than 300 renowned doctors, providing 24/7 medical services [5]. - A specific case from Shanghai's Huangpu District demonstrates the effectiveness of the "digital family doctor" AI avatar, which serves 400,000 residents and helps alleviate the service pressure on family doctors [5]. Group 3: User-Centric Product Development - Since its beta launch, AQ has served over 140 million users, with nearly 60% from third-tier cities and below, indicating a strong demand for accessible AI health services in these regions [7]. - New features like the "health record" function and the "AI anti-fraud hotline" have been introduced to address specific user needs, particularly for elderly individuals [7]. Group 4: Challenges in AI Healthcare - The application of AI in healthcare requires careful consideration of issues such as high-quality data accumulation, model hallucination suppression, and ethical technology development [9]. - Ant Group's CEO emphasized that AI should serve as a supportive tool for doctors, enhancing their efficiency and service reach rather than replacing them [11].

Core Insights - Ant Group's AI health application AQ launched new features focusing on family health management and fraud prevention for the elderly, including a "Health Record" and an "AI Fraud Prevention Hotline" in collaboration with China Mobile [1][2] - Since its beta launch in September last year, AQ has served over 140 million users, with nearly 60% from third-tier cities and below [1] Group 1: Product Features - The upgraded "Health Record" integrates medical history, medication records, and lifestyle information, supporting data from ten major brands of smartphones and wearable devices [2] - AQ's "AI Skin Detection" can identify over 50 skin diseases, and users can assess their health through tongue, hair, and facial scans for personalized health advice [2] - The "AI Fraud Prevention Hotline" allows elderly users to easily access AI doctors for immediate assistance with suspicious information or health issues [2] Group 2: Service Connectivity - AQ connects nearly one million real doctors and facilitates online consultations with over 200,000 doctors through the Good Doctor platform, providing 24/7 medical services [3] - The "Digital Family Doctor" AI assistant is already operational in over 200 family doctors' AI avatars in Shanghai's Huangpu District, serving 400,000 residents and one million professionals [3] Group 3: Future Directions - Ant Group's CEO emphasized that AI should assist doctors rather than replace them, and the company is investing in AI-enabled multidisciplinary consultations and addressing data quality and ethical issues [3]

Core Insights - Ant Group's AI health application AQ launched new features focused on family health management and fraud prevention for the elderly, including a "Health Record" and an "AI Fraud Prevention Hotline" in collaboration with China Mobile [1][3] - Since its beta launch in September last year, AQ has served over 140 million users, with nearly 60% from lower-tier cities, aiming to enhance precision and inclusive healthcare [1][2] Product Features - The upgraded "Health Record" allows comprehensive management of medical history, medication, and lifestyle information, supporting data integration from ten major brands of smartphones and health devices [2][3] - The "AI Skin Detection" feature can identify over 50 skin diseases and provide personalized health advice based on various health assessments [2] Target Audience and Accessibility - The "AI Fraud Prevention Hotline" enables elderly users to easily access AI doctors for immediate assistance with suspicious information or health issues [3] - AQ aims to provide a "health steward" for every family in China, addressing healthcare needs across urban and rural areas [3][6] AI Integration in Healthcare - AQ launched an open platform for doctors to develop personalized AI assistants, enhancing the capabilities of both renowned and grassroots medical professionals [6][7] - The platform connects nearly one million real doctors and facilitates online consultations, aiming to improve healthcare service delivery [6] Community Impact - The "Digital Family Doctor" AI assistant is already operational in Shanghai, providing 24-hour health consultation services to local residents [7] - Ant Group emphasizes that AI should serve as a supportive tool for doctors rather than a replacement, focusing on ethical considerations and high-quality data accumulation in AI healthcare applications [7]